Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 4Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 958Urinary Bladder Neoplasms 264Carcinoma, Renal Cell 251Kidney Neoplasms 146Carcinoma, Transitional Cell 130Breast Neoplasms 128Neoplasms 122Colorectal Neoplasms 97Ovarian Neoplasms 91Melanoma 86Carcinoma, Non-Small-Cell Lung 84Lung Neoplasms 81Neoplasm Metastasis 79Pancreatic Neoplasms 68Non-Muscle Invasive Bladder Neoplasms 68Uterine Cervical Neoplasms 58Stomach Neoplasms 55Head and Neck Neoplasms 51Squamous Cell Carcinoma of Head and Neck 47Endometrial Neoplasms 47Adenocarcinoma 46Esophageal Neoplasms 44Testicular Neoplasms 42Sarcoma 41Carcinoma, Hepatocellular 41Disease 33Triple Negative Breast Neoplasms 32Liver Neoplasms 30Colonic Neoplasms 29Metastatic Castration-resistant Prostate Cancer 25

Interventions

darolutamide 2Androgen Antagonists 2relugolix 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Metastatic Hormone-sensitive Prostate Cancer (mHSPC) × Genitourinary × Clear all
NCT07395804 2026-05-29

23146

Bayer

Recruiting
500 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06661122 2026-05-19

HAYATE

Bayer

Recruiting
100 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07241416 2026-05-11

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
206 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07216248 2025-10-29

OPTIMAS

University of Utah

Phase 2 Recruiting
160 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡